Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-019C in Relapse/Refractory Autoimmune Diseases
NCT07410377Phase 1Withdrawn
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in systemic lupus erythematosus (SLE) and inflammatory myopathy (IIM), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Dose-Limiting Toxicity at 28 days, Safety and Tolerability at 2 years and 1 more. Planned start Mar 2026; status: withdrawn.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
systemic lupus erythematosus (SLE)inflammatory myopathy (IIM)
Beyond the preview
Go deeper on NCT07410377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410377.